Form 10-Q HALOZYME THERAPEUTICS, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Halozyme Therapeutics (HALO) PT Raised to $58 at Leerink Partners
November 1, 2024 7:21 AM EDTLeerink Partners analyst David Risinger raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $58.00 (from $56.00) while maintaining a Market Perform rating.
The analyst comments "Bottom line: We revised our model post-3Q results and bumped our DCF-derived PT from $56 to $58 (we... More
